INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
Scope & Guideline
Unveiling the science behind effective therapeutics.
Introduction
Aims and Scopes
- Clinical Pharmacokinetics and Pharmacodynamics:
The journal publishes research on the absorption, distribution, metabolism, and excretion (ADME) of drugs, as well as their pharmacological effects, highlighting studies that explore how various factors influence drug behavior in the body. - Therapeutic Drug Monitoring and Optimization:
There is a strong emphasis on studies that assess therapeutic drug monitoring (TDM) practices to optimize medication efficacy and minimize toxicity, particularly in vulnerable populations such as those with renal impairment or undergoing chemotherapy. - Pharmacovigilance and Drug Safety:
The journal includes articles on post-marketing surveillance, adverse drug reactions, and safety profiles of medications, underscoring the importance of pharmacovigilance in clinical practice. - Bioequivalence and Drug Formulation Studies:
Research on the bioequivalence of drug formulations and their implications for therapeutic efficacy is a core area, reflecting the journal's commitment to ensuring that generic and branded medications provide similar therapeutic outcomes. - Impact of Comorbidities on Pharmacotherapy:
The journal frequently publishes studies examining how comorbid conditions affect drug therapy, especially in populations with complex health needs, such as the elderly or those with chronic diseases. - Network Pharmacology and Traditional Medicine:
Emerging themes include the use of network pharmacology to understand drug interactions and the efficacy of traditional medicine, particularly in the context of integrative approaches to therapy.
Trending and Emerging
- COVID-19 Treatment and Drug Interactions:
A significant increase in research related to COVID-19, including drug interactions and treatment efficacy, underscores the pandemic's impact on clinical pharmacology and the urgency for effective therapeutic strategies. - Real-World Evidence and Patient-Centered Research:
There is a growing emphasis on real-world evidence studies that assess drug efficacy and safety in diverse patient populations, moving beyond controlled clinical trial settings to understand practical therapeutic outcomes. - Network Pharmacology and AI in Drug Research:
The utilization of network pharmacology and artificial intelligence to analyze drug interactions and therapeutic targets is gaining traction, indicating a modern approach to drug discovery and personalized medicine. - Polypharmacy and Drug-Drug Interactions:
Research focused on polypharmacy, particularly in geriatric populations, is on the rise, reflecting concerns about adverse drug interactions and the need for careful medication management. - Therapeutic Strategies for Chronic Diseases:
Emerging studies are increasingly addressing therapeutic strategies for managing chronic diseases, such as diabetes and cardiovascular conditions, highlighting the need for tailored pharmacotherapy in these populations.
Declining or Waning
- Basic Pharmacology Studies:
There appears to be a waning interest in basic pharmacological studies that do not directly translate into clinical applications, as the journal increasingly prioritizes research with immediate clinical relevance. - Non-Clinical Trial Research:
The publication of studies that focus solely on non-clinical trial methodologies or theoretical frameworks has decreased, indicating a preference for clinical trial data and real-world evidence. - Historical Drug Use Studies:
Research focusing on historical trends in drug use or retrospective analyses that do not incorporate current clinical guidelines or practices is less frequently featured, suggesting a pivot towards more contemporary, applicable research. - Single-Agent Pharmacotherapy:
There is a noticeable decline in studies examining the effects of single-agent therapies, as the journal increasingly highlights multi-drug regimens and combination therapies that reflect real-world clinical practice. - Pharmacogenomics:
Although pharmacogenomics remains important, there has been a relative decrease in the number of studies dedicated solely to genetic factors influencing drug response, as more integrated approaches are favored.
Similar Journals
Journal of Pharmaceutical Health Care and Sciences
Bridging disciplines to elevate pharmaceutical practices.The Journal of Pharmaceutical Health Care and Sciences is a premier open access journal published by BMC that aims to advance the field of pharmaceutical sciences by providing high-quality research and comprehensive reviews across various domains including pharmacology, nursing, and healthcare. With an impact factor reflecting its relevance and rigor, the journal has established itself as a significant platform for disseminating knowledge since its inception in 2015. The journal is indexed in Scopus, currently holding a position in the Q3 quartile for medical pharmacology and Q2 quartile for nursing pharmacology, indicating its growing influence and reach in the scientific community. Based in the United Kingdom with a commitment to open access, the Journal of Pharmaceutical Health Care and Sciences ensures that all researchers, professionals, and students have free access to vital research that fosters innovation and improves healthcare outcomes worldwide. With a focus on collaborative and multidisciplinary approaches, the journal invites contributions that align with its objectives of enhancing health care delivery and pharmaceutical practices.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Fostering Excellence in Pharmacological ResearchBritish Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.
International Journal of Pharmacology
Fostering Global Dialogue in Pharmacology and ToxicologyWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
Empowering Animal Health with Cutting-Edge PharmacologyJOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS is a crucial publication in the field of veterinary medicine, dedicated to advancing knowledge and practices related to pharmacology and therapeutic interventions in animals. Published by WILEY, this peer-reviewed journal has been a reliable source of innovative research since its inception in 1978, and it continues to play an integral role in shaping veterinary pharmacology through its commitment to high-quality scientific discourse. With an impact factor reflective of its robust academic standing, the journal is categorized in the Q3 quartile for Pharmacology and Q2 for Veterinary (miscellaneous) as of 2023, highlighting its relevance and significance within these domains. It is indexed in Scopus with commendable rankings, particularly in General Veterinary, where it ranks #45 out of 194, placing it in the 77th percentile. This journal not only offers a platform for original research articles but also caters to the dissemination of practical applications and reviews that are essential for veterinarians, researchers, and students alike in enhancing animal health and welfare. Although not an open-access publication, its contributions remain accessible to those engaged in the veterinary sciences through institutional subscriptions. The journal's enduring legacy and forward-looking approach make it a vital resource for anyone interested in veterinary therapeutics and pharmacology.
DRUGS IN R&D
Exploring the latest breakthroughs in drug R&D.DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.
BIOLOGICAL & PHARMACEUTICAL BULLETIN
Advancing the Frontiers of Biomedicine and Drug DevelopmentBIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.
ACTA POLONIAE PHARMACEUTICA
Pioneering Research in Pharmaceutical TechnologyACTA POLONIAE PHARMACEUTICA is a well-established peer-reviewed journal published by Polskie Towarzystwo Farmaceutyczne, dedicated to the field of pharmaceutical sciences and pharmacology. With a rich history dating back to 1951, this journal serves as a vital platform for disseminating cutting-edge research and developments in pharmaceutical technology, drug development, and therapeutic therapies. Although it currently operates under a subscription model, its commitment to scientific rigor has earned it a respectable impact factor, placing it in the Q3 and Q4 quartiles respectively for Pharmaceutical Science and Pharmacology as of 2023. Researchers and practitioners alike will find value in its comprehensive coverage of essential topics, as well as its diverse range of contributions from both established and emerging scholars in the field. With its address located in the heart of Warsaw, Poland, ACTA POLONIAE PHARMACEUTICA aims to further bridge the gap between academia and industry, paving the way for innovation in drug discovery and therapeutic applications.
Drug Discoveries and Therapeutics
Empowering researchers with cutting-edge insights.Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.
DRUG DEVELOPMENT RESEARCH
Driving the evolution of medicine with impactful research.DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.
Drug Design Development and Therapy
Driving Innovation in Pharmacology and Therapeutic SolutionsDrug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.